Subtype
Malignant Anorectal Neoplasm
CI-CAN-00005864Explore in graph →
450 active trials1 approved drugs6 evidence items
- NCIt
- C215225
Loading cancer entity…
Subtype
CI-CAN-00005864Explore in graph →
Clinical trials
1,781 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (174)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07810114 | Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer(SPARE) | not yet recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811076 | Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer(SG-RCT) | not yet recruiting | Phase 1 / Phase 2 | 140 | Xuelei Ma MDOTHER | 1 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT07779694 | 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer | not yet recruiting | Phase 2 | 51 | Zhejiang UniversityOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07774754 | Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial(RADIANT) | not yet recruiting | Phase 2 | 18 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07765667 | NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC(CRI-KEV) | not yet recruiting | Phase 2 | 100 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07209215 | ctDNA-Informed Management of Early-Stage Rectal Cancer(ULTIMATE) | not yet recruiting | Phase 2 | 200 | University of California, DavisOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07580339 | Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | not yet recruiting | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07680088 | Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer | not yet recruiting | Phase 2 | 17 | University of Texas Southwestern Medical CenterOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07651007 | Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR | not yet recruiting | Phase 2 | 29 | Wang XinOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT07645118 | Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer(IMPERIA) | not yet recruiting | Phase 2 | 10 | Dr. Te VuongOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07622017 | KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer(K-BOOST) | not yet recruiting | Phase 2 | 24 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07581626 | Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer | not yet recruiting | Phase 2 | 20 | Chongqing University Cancer HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07527520 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial | not yet recruiting | Phase 2 | 165 | Fudan UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07509424 | Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance | not yet recruiting | Phase 2 | 29 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Apr 3, 2026 | clinicaltrials |
| NCT07469306 | Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 130 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07397442 | Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 19 | Beijing Friendship HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402486 | A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer | not yet recruiting | Phase 2 | 20 | Siriraj HospitalOTHER | 0 | Feb 11, 2026 | clinicaltrials |
| NCT07394192 | Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer(PKUCH- R11) | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07381400 | Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) | not yet recruiting | Phase 2 | 128 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT07381777 | XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients(IMMUNOSTAR) | not yet recruiting | Phase 2 | 270 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07321847 | Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases(INJECTABL-3) | not yet recruiting | Phase 2 / Phase 3 | 717 | Immunophotonics, Inc.INDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07314528 | Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer | not yet recruiting | Phase 2 | 42 | St. James's Hospital, IrelandOTHER | 0 | Jan 2, 2026 | clinicaltrials |
| NCT07297030 | SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07248020 | A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue(BCMRECRAD) | not yet recruiting | Phase 2 | 72 | Chang Gung Memorial HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07243938 | Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | not yet recruiting | Phase 2 | 70 | Tao ZhangOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07175636 | QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07161115 | Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer(REFIRT) | not yet recruiting | Phase 2 | 60 | Longhao LiOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Changhai HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07059949 | Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer(Union-mRC) | not yet recruiting | Phase 2 | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT06057831 | PET/MRI in Rectal Cancer | not yet recruiting | Phase 2 | 40 | AHS Cancer Control AlbertaOTHER | 0 | Jun 18, 2025 | clinicaltrials |
| NCT06919510 | A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06872606 | Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer(SCRIPBOT) | not yet recruiting | Phase 2 | 33 | Sir Run Run Shaw HospitalOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06760520 | Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jan 8, 2025 | clinicaltrials |
| NCT06751394 | Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer(TRACER) | not yet recruiting | Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06665087 | CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC | not yet recruiting | Phase 2 | 110 | Fudan UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | not yet recruiting | Phase 2 | 124 | Fudan UniversityOTHER | 0 | Oct 28, 2024 | clinicaltrials |
| NCT06599827 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC(iMHRT-LARC) | not yet recruiting | Phase 2 | 54 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06443671 | Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer(PKUCH-R09) | not yet recruiting | Phase 2 / Phase 3 | 132 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06390982 | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06255379 | Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 52 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06304545 | Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab | not yet recruiting | Phase 2 | 48 | Harbin Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06014944 | Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody(PMMR/MSS) | not yet recruiting | Phase 2 | 30 | Changhai HospitalOTHER | 0 | Aug 31, 2023 | clinicaltrials |
Data updated 20 days agoSource updated Sep 9, 2026source: clinicaltrials